Article Text

Download PDFPDF

Subject index

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

abscopal effect, A5A2609.03P08.02

Acute myeloid leukemia, A31P09.01

Adoptive Cell Therapy, A25A38P08.01P09.13

adoptive cellular therapy, A40P09.17

Adoptive T cell therapy, A3A9A3209.01P01.03P09.02

AML, A24A25A36P07.01P07.02P09.10

AML chemotherapy, A27P08.05

anaplastic thyroid carcinoma, A22P06.01

anti-PD1, A509.03

antibodies, A19P03.05

antibody therapy, A103.06

APEX proximity labeling, A9P01.04

B cell, A13P02.03

barcoded-multimer, A308.03

Bifunctional antibodies, A712.05

Bispecific monoclonal antibody, A8P01.01

Bispecific antibody, A409.02

bladder cancer, A2A2706.04P08.04

brain tumors, A18A38P03.04P09.13

Breast cancer, A29P08.08

bystander killing, A8P01.01

CAF09b, A16P03.01

cancer immunotherapies, A21P04.03

cancer immunotherapy target, A19P03.07

Cancer nanomedicine, A43P09.22

Cancer Testis Antigen, A29P08.08

Cancer Vaccine, A17A18P03.03P03.04

Cancer-Immunotherapy, A103.05

cancer_vaccine, A19P03.05

CAR T cells, A3A22A23A32A35A36A709.01P06.01P06.02P09.02P09.06P09.0912.04

carcinoma, A33P09.03

CD155, A33P09.03

CD20, A103.06

CD38, A612.03

CD40-activated B cells (CD40Bs),A24P06.04

CD47, A612.03

CD8 T cell Cooperation, A35P09.07

CD8+ T cells, A42P09.20

Cell therapy, A409.02

Chemokine-receptor interaction, A9P01.04

Chimeric antigen receptor (CAR) T cells, A31P09.01

chromatin, A16P02.09

colorectal cancer, A14A29P02.06P08.07

Combination immunotherapy, A206.03

combinatorial therapy, A28P08.06

companion diagnostics, A21P04.03

complement activation, A103.06

CRC, A42P09.19

CRISPR screen, A30P08.09

ctDNA, A21P04.02

CTLA-4, A36P09.10

cystatin F, A33P09.04

cysteine cathepsins, A33P09.04

cytarabine resistance, A27P08.05

Cytokine-Induced Killer cells, A25P08.01

cytotoxicity, A8P01.02

Dendritic Cells, A25P07.02

dexamethasone, A37P09.11

electrochemotherapy, A26P08.03

Endogenous retrovirus, A17A40P03.03P09.16

Entropy, A15P02.07

EVs, A24P07.01

fully automated platform, A12P02.02

Galectin-9, A11P01.07

gastric adenocarcinoma, A37P09.11

gene regulation, A16P02.09

gene therapy, A26P08.03

Glioblastoma, A15A39P02.08P09.14

granule-dependent cytotoxicity, A33P09.04

gut microbial metabolites, A37P09.11

Head and neck squamous cell carcinomas, A36P09.08

Hepatocellular carcinoma, A15P02.07

HERV-K, A19P03.05

high throughput screening, A28P08.06

HLA system, A38P09.12

HLA-G, A10P01.06

HNSCC, A39P09.15

HVEM, A12P02.01

IL-2, A509.03

IL-22, A33P09.03

ILC2, A14P02.06

Immune cell infiltration, A43P09.23

immune cell killing, A28P08.06

immune cell landcape evolution, A15P02.08

Immune checkpoint blockade, A18P03.04

immune checkpoint inhibitor, A14A2A27P02.0506.04P08.04

immune checkpoint targeting, A10P01.06

Immune escape, A38P09.12

Immune evasion, A11P01.07

immune monitoring, A20P04.01

Immune Profiling, A13P02.04

Immunology, A42P09.20

Immunomodulation, A25A36P07.02P09.10

Immunosuppression, A23P06.03

immunotherapy, A14A20A22A24A30A32A35A35P02.06P03.08P05.01P06.04P08.09P09.02P09.06P09.07

Indoleamine-2,3-dioxygenase, A39P09.14

Influenza, A41P09.18

Innate Cell Engagers, A612.03

Innate immune checkpoint blockade, A712.05

interleukin-12, A26P08.03

Jurkat cells, A8P01.02

Killer Ig-Like Receptors, A42P09.20

LDHC, A29P08.08

lectins, A8P01.02

leukaemia, A308.03

leukemia derived DC, A20P04.01

Liquid Biopsy, A21P04.02

liver hepatocellular carcinoma, A12P02.01

Lymphoma, A34P09.05

Lysosome, A34P09.05

Macrophages, A35P09.07

Malignant Pleural Effusions, A30P08.10

medicines authorisation, A21P04.03

Melanoma, A409.02

MelARV, A40P09.16

Microbiome, A14P02.05

miRNA, A24P07.01

Molecular mimicry, A19P03.06

MRD, A21P04.02

Multiplex immunofluorescence, A12P02.02

Myeloid, A15P02.07

Neoantigen, A38P09.12

neoantigen-specific TCR, A40P09.17

neoepitope, A308.03

nephroblastoma, A43P09.23

Neuroblastoma, A2A7A23A3006.0312.05P06.03P08.09

NSCLC, A22P05.01

Nucleolin, A23P06.02

oncolytic virotherapy, A43P09.21

oncolytic virus, A7A39A4112.04P09.15P09.18

Organ-on-a-chip, A10P01.05

organoids, A42P09.19

Pancreatic Adenocarcinoma, A13P02.03

Pathogen antigens, A19P03.06

PD-1 gene silencing, A9P01.03

Peptide vaccine, A16A17P03.01P03.02

Personalised immunotherapy, A11P01.07

Personalized tumor vaccine, A20P03.08

photodynamic therapy, A27P08.04

PLAP (placental alkaline phosphatase),A8P01.01

Platelets, A22P05.01

Programmed Death-1 inhibitors, A39P09.14

prostate cancer, A17P03.02

prostatic acid phosphatase, A17P03.02

Protom pump inhibitors, A14P02.05

Radiochemoimmunotherapy, A26P08.02

Radiotherapy, A30P08.10

rational design, A43P09.22

resistance, A509.04

Robo4, A103.05

ROR1 receptor, A22P06.01

screening of therapeutic inhibitors, A9P01.04

ScRNA sequencing, A15P02.08

Self-Antigen, A103.05

Single-cell RNA sequencing, A31P09.01

slice cultures, A39P09.15

Solid tumor, A25P08.01

Spatial Biology, A13P02.04

spatial model, A43P09.21

STING, A30P08.10

Stress Granules, A29P08.07

T cell death, A509.04

T cell engineering, A40P09.17

t cell exhaustion, A16P02.09

T cell factor 1 (TCF-1),A9P01.03

T cell lymphoma, A36P09.09

T cell response, A20P03.08

T cells, A10A23P01.05P06.03

Targeted therapy, A206.04

Tertiary Lymphoid Structures, A13P02.03

Therapeutic concepts, A34P09.05

therapeutic resistance, A43P09.21

TIGIT, A206.03

TNF, A41P09.18

Transmigration, A10P01.05

Treg depletion, A509.04

Triple negative breast cancer, A23P06.02

tumor associated macrophages, A42P09.19

tumor immunotherapy, A12P02.01

Tumor microenvironment, A3A10A12A35A36A3809.01P01.06P02.02P09.06P09.08P09.13

Tumor-associated antigens, A16A19A24A7P03.01P03.06P06.0412.04

Virus-Encoded Virus-Like-Particles, A17P03.03

Virus-like vaccine, A40P09.16

VOCs above serum and cell culture supernatants, A20P04.01

Vpx protein, A27P08.05